Equivalence / Non-Inferiority Trial
Equivalence and Non-Inferiority Clinical Trial Design · Also known as: non-inferiority trial, bioequivalence study, active-control trial, Denklik ve Üstünlük Olmayan Çalışma (Equivalence / Non-Inferiority)
An equivalence or non-inferiority trial is a clinical study design that tests whether a new intervention is clinically equivalent to, or no worse than, an established standard by a pre-specified margin. Codified in Schuirmann's 1987 Two One-Sided Tests (TOST) framework and embedded in EMA and FDA regulatory guidance, this design is the regulatory standard for generic drug approval and medical device testing.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use this design when a placebo arm is unethical or impractical and the question is whether a new treatment (typically cheaper, safer, or more convenient) is clinically equivalent to or not worse than an existing standard. The outcome can be continuous or binary. Key assumptions: the equivalence margin Δ must be set before data collection based on clinical and regulatory grounds; the constancy assumption must hold in active-control trials (historical evidence that the control beats placebo remains valid in the current population); sample sizes are typically larger than in superiority trials; and the per-protocol population is the primary analysis set.
Strengths & limitations
- Provides a direct, clinically interpretable answer to whether differences are too small to matter.
- The regulatory standard for generic drug approval (FDA, EMA) and medical device licensing.
- TOST framework gives exact control of the Type I error at the 5% level for both one-sided tests simultaneously.
- Can demonstrate practical usefulness of a new agent even when it cannot surpass a well-established standard.
- Sample sizes are substantially larger than superiority trials for the same effect size and power.
- The equivalence margin Δ requires external clinical or regulatory justification; arbitrary choices invalidate conclusions.
- The constancy assumption in active-control trials is difficult to verify and often contested.
- Bias toward the null (both-treatments-similar) — poor study quality can spuriously support equivalence.
Frequently asked
Why is a 90% confidence interval used instead of 95%?
The TOST framework runs two one-sided tests simultaneously, each at the 5% significance level. The intersection of the two rejection regions corresponds to a 90% two-sided CI. Using a 95% CI would make the test more conservative, equivalent to running each one-sided test at 2.5%.
How is the equivalence margin Δ chosen?
The margin must be grounded in clinical evidence — typically the smallest difference that patients or clinicians would consider meaningful — and pre-specified in the study protocol. For bioequivalence, regulatory agencies set standard windows (e.g., 80–125% for AUC and Cmax). In active-control trials the margin is often derived as a fraction of the control's historical effect over placebo.
Can a non-inferiority trial also demonstrate superiority?
Yes. If the 90% CI lies entirely above zero as well as above −Δ, the study has shown superiority. This hierarchical testing — non-inferiority first, then superiority — is pre-specified in many modern protocols and requires no alpha adjustment because non-inferiority is tested first.
What is the constancy assumption and when does it matter?
In active-control equivalence trials (no placebo arm), the inference that the new treatment is effective depends on assuming that the control still has the same efficacy it showed in historical placebo-controlled trials. If patient populations, standard of care, or outcome definitions have shifted, the constancy assumption may not hold, which undermines the logical chain of the equivalence argument.
Sources
How to cite this page
ScholarGate. (2026, June 1). Equivalence and Non-Inferiority Clinical Trial Design. ScholarGate. https://scholargate.app/en/experimental-design/equivalence-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Clinical Trial DesignExperimental design↔ compare
- Crossover DesignExperimental design↔ compare
- Equivalence Test (TOST)Statistics↔ compare
- Power Analysis for t-testStatistics↔ compare
- Randomized Controlled TrialExperimental design↔ compare
- Sequential AnalysisStatistics↔ compare